drugset / Trial / NCT00478725

Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034

NCT00478725

Phase 1 Completed 10 enrolled GlaxoSmithKline
RandomizedSingle-groupOpen-labelTreatment

Summary

To study the absorption, distribution, metabolism and excretion of GW786034, and the absorption of a single IV dose of GW786034

Timeline

Start
2007-07-18
Primary completion
2008-07-01
Completion
2008-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Pazopanib Small molecule 5 mg Oral
Subject Pazopanib Small molecule 400 mg Oral
Subject Pazopanib Small molecule 800 mg Oral

Indications